Payment overview · 2025
General Payments
$86.85
5 reported records · 3 companies
Healthcare provider profile · identity verified
Martin Wayne Dillow, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHANUTE, KS · NPI 1073730867
Verified facts
What the public records show
CMS Open Payments records show Martin Wayne Dillow, MD received $86.85 in general payments during 2025 across 5 reported records.
Supernus Pharmaceuticals, Inc. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.75 | 40.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.01 | 38.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.09 | 22.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $86.85 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 745 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 63 |
| Lisinopril | Lisinopril | 344 | 90 |
| Losartan Potassium | Losartan Potassium | 317 | 77 |
| Omeprazole | Omeprazole | 294 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 38 |
| Carvedilol | Carvedilol | 188 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 41 |
| Alprazolam | Alprazolam | 164 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 44 |
| Eliquis | Apixaban | 159 | 24 |
| Furosemide | Furosemide | 158 | 43 |
| Tramadol Hcl | Tramadol Hcl | 140 | 36 |
| Metformin Hcl Er | Metformin Hcl | 136 | 35 |
| Gabapentin | Gabapentin | 134 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 25 |
| Warfarin Sodium | Warfarin Sodium | 129 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 125 | 19 |
| Sertraline Hcl | Sertraline Hcl | 125 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 34 |
| Potassium Chloride | Potassium Chloride | 116 | 31 |
| Meloxicam | Meloxicam | 109 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 19 |
| Alendronate Sodium | Alendronate Sodium | 99 | 22 |
| Trazodone Hcl | Trazodone Hcl | 97 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 13 |
| Simvastatin | Simvastatin | 91 | 21 |
| Mirtazapine | Mirtazapine | 88 | 12 |
| Glimepiride | Glimepiride | 87 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Spironolactone | Spironolactone | 77 | 20 |
| Memantine Hcl | Memantine Hcl | 76 | suppressed |
| Famotidine | Famotidine | 73 | 18 |
| Finasteride | Finasteride | 69 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 19 |
| Donepezil Hcl | Donepezil Hcl | 67 | suppressed |
| Prednisone | Prednisone | 64 | 50 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 14 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | 17 |
| Metformin Hcl | Metformin Hcl | 54 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 13 |
| Pregabalin | Pregabalin | 51 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 11 |
| Atenolol | Atenolol | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Farxiga | Dapagliflozin Propanediol | 42 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 23 |
| Vilazodone Hcl | Vilazodone Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 28 |
| Ketoconazole | Ketoconazole | 35 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $86.85 · 5 records | Supernus Pharmaceuticals, Inc. | ELIQUIS, EVENITY, NURTEC ODT, PROLIA, Qelbree | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error